8-K: Beyond Air Enters $35 Million At-The-Market Equity Offering Agreement

Beyond Air, Inc. has entered into an agreement with BTIG, LLC to sell up to $35 million of its common stock through an at-the-market equity offering.

Summary

• Beyond Air, Inc. has entered into an At-The-Market Equity Offering Sales Agreement with BTIG, LLC, as the sales agent, on February 14, 2025.
• The company may offer and sell shares of its common stock, with an aggregate offering price of up to $35,000,000, from time to time at its discretion.
• Due to offering limitations, the initial prospectus supplement registers the sale of shares with an aggregate gross sales price of up to $9,892,518.
• The company may file another prospectus supplement to sell additional amounts if its public float increases.
• BTIG will use commercially reasonable efforts to sell the common stock based on instructions from Beyond Air.
• The company will pay BTIG a commission of up to 3% of the gross sales proceeds.
• The offering will terminate upon the sale of all common stock or termination of the agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which can be seen as a positive, it also introduces potential dilution for existing shareholders. The terms of the agreement appear standard for this type of offering.

Positives

• The agreement provides Beyond Air with flexibility in raising capital.
• The at-the-market offering allows the company to sell shares gradually, potentially minimizing market impact.
• The company is not obligated to make any sales of common stock under the agreement.

Negatives

• The offering could dilute existing shareholders' ownership.
• The company will incur commissions and other expenses related to the offering.
• The company's stock price could be negatively impacted by the increased supply of shares.

Risks

• The company may not be able to sell all of the shares offered.
• Market conditions could make it difficult to sell shares at favorable prices.
• The offering could be terminated before all shares are sold.

Future Outlook

The company may file another prospectus supplement to sell additional amounts if its public float increases, indicating a potential for further capital raising activities.

Industry Context

At-the-market offerings are a common way for companies, particularly those in the biotech and pharmaceutical industries, to raise capital. This type of offering provides flexibility and can be less dilutive than traditional underwritten offerings.

Comparison to Industry Standards

• Comparable companies such as BioCryst Pharmaceuticals and Catalyst Pharmaceuticals have utilized ATM offerings to fund research and development or commercialization efforts.
• The commission rate of up to 3% is within the typical range for ATM offerings.
• The size of the offering, $35 million, is relatively small compared to some larger biotech companies but is significant for a company of Beyond Air's size.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company will have access to additional capital to fund its operations.
• BTIG will receive commissions from the sale of shares.

Next Steps

• BTIG will begin selling shares of Beyond Air's common stock based on instructions from the company.
• The company may file additional prospectus supplements to sell more shares if its public float increases.
• The offering will continue until all shares are sold or the agreement is terminated.

Key Dates